Anna Sureda, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, discusses the future directions of CAR T-cell therapy in lymphoma. The availability of CAR-T has modified the treatment algorithm for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Indications for CAR T-cell therapy will likely expand to earlier lines of treatment and other lymphomas. Dr Sureda is looking forward to the data from three Phase III clinical trials comparing CAR T-cell therapies with autologous stem cell transplantation in patients with primary refractory disease. Additionally, strategies to improve efficacy and toxicity are certainly desirable. This interview took place during the 3rd European CAR T-cell Meeting.
Honoraria from Gilead Kite, Novartis and Celgene/BMS